BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Depression and Fatigue in MS Patients Treated With Betaferon.

Completed

Conditions: Multiple Sclerosis

Interventions: Biological: Interferon beta-1b (Betaferon, BAY86-5046)

First Posted Date: 2011-05-17

Last Posted Date: 2015-01-21

Lead Sponsor: Bayer

Target Recruit Count: 567

Registration Number: NCT01354665

Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)

Phase 1

Completed

Conditions: Nasal Congestion

Interventions: Drug: Phenylephrine HCl Extended Release
Drug: Phenylephrine HCl Immediate Release

First Posted Date: 2011-05-16

Last Posted Date: 2015-02-23

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01354418

Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer

Withdrawn

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2011-05-16

Last Posted Date: 2015-01-30

Lead Sponsor: Bayer

Registration Number: NCT01353794

Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

Phase 1

Completed

Conditions: Hypertension, Essential

Interventions: Drug: Nifedipine/Candesartan (BAY 98-7106)
Drug: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)

First Posted Date: 2011-05-10

Last Posted Date: 2015-12-10

Lead Sponsor: Bayer

Target Recruit Count: 49

Registration Number: NCT01350609

Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study

Phase 1

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Vardenafil ODT, (Staxyn, BAY38-9456)
Drug: Placebo

First Posted Date: 2011-05-06

Last Posted Date: 2014-05-19

Lead Sponsor: Bayer

Target Recruit Count: 42

Registration Number: NCT01348880

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: BAY94-8862
Drug: Placebo
Drug: Spironolactone

First Posted Date: 2011-05-02

Last Posted Date: 2022-02-10

Lead Sponsor: Bayer

Target Recruit Count: 457

Registration Number: NCT01345656

Gadobutrol Enhanced MRA of the Renal Arteries

Phase 3

Completed

Conditions: Renal Artery Obstruction

Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2011-04-29

Last Posted Date: 2015-08-26

Lead Sponsor: Bayer

Target Recruit Count: 317

Registration Number: NCT01344460

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Phase 3

Completed

Conditions: Carotid Stenosis

Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2011-04-29

Last Posted Date: 2019-01-04

Lead Sponsor: Bayer

Target Recruit Count: 479

Registration Number: NCT01344447

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)

First Posted Date: 2011-04-20

Last Posted Date: 2014-10-01

Lead Sponsor: Bayer

Target Recruit Count: 53

Registration Number: NCT01339104

A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)

Phase 1

Completed

Conditions: Heartburn

Interventions: Drug: omeprazole/sodium bicarbonate
Drug: omeprazole magnesium

First Posted Date: 2011-04-19

Last Posted Date: 2015-02-23

Lead Sponsor: Bayer

Target Recruit Count: 50

Registration Number: NCT01337804

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy